Prostate cancer (CaP) is the second leading cause of cancer-related deaths in North American males and the most common newly diagnosed cancer in men world wide. Biomarkers are widely used for both early detection and prognostic tests for cancer. The current, commonly used biomarker for CaP is serum prostate specific antigen (PSA). However, the specificity of this biomarker is low as its serum level is not only increased in CaP but also in various other diseases, with age and even body mass index. Human body fluids provide an excellent resource for the discovery of biomarkers, with the advantage over tissue/biopsy samples of their ease of access, due to the less invasive nature of collection. However, their analysis presents challenges in te...
International audienceSimple Summary Despite intensive research, effective tools for detection and m...
International audienceSimple Summary Despite intensive research, effective tools for detection and m...
Early detection of prostate cancer is problematic due to the lack of a marker that has high diagnost...
Prostate cancer is the second most frequently diagnosed non-skin cancer in men worldwide. Patient ou...
Prostate cancer is the second most frequently diagnosed non-skin cancer in men worldwide. Patient ou...
Prostate cancer is the second most frequently diagnosed non-skin cancer in men worldwide. Patient ou...
© 2017 Elsevier B.V. Prostate cancer (CaP) is the most common cancer in men and the second leading c...
Prostate Cancer (PCa) is the second most commonly diagnosed cancer in men worldwide. Although increa...
Prostate cancer (PCa) is the most common cancer diagnosis and the second most common cause of cancer...
Despite advances in molecular medicine, genomics, proteomics and translational research, prostate ca...
Prostate cancer (PCa) is the most common cancer diagnosis and the second most common cause of cancer...
Prostate cancer (PCa) is the most common cancer diagnosis and the second most common cause of cancer...
Prostate cancer (PCa) is the most common cancer diagnosis and the second most common cause of cancer...
The marker currently used for prostate cancer (CaP) detection is an increase in serum prostate-speci...
Prostate cancer (PCa) is one of the most frequently diagnosed cancer among men in the western societ...
International audienceSimple Summary Despite intensive research, effective tools for detection and m...
International audienceSimple Summary Despite intensive research, effective tools for detection and m...
Early detection of prostate cancer is problematic due to the lack of a marker that has high diagnost...
Prostate cancer is the second most frequently diagnosed non-skin cancer in men worldwide. Patient ou...
Prostate cancer is the second most frequently diagnosed non-skin cancer in men worldwide. Patient ou...
Prostate cancer is the second most frequently diagnosed non-skin cancer in men worldwide. Patient ou...
© 2017 Elsevier B.V. Prostate cancer (CaP) is the most common cancer in men and the second leading c...
Prostate Cancer (PCa) is the second most commonly diagnosed cancer in men worldwide. Although increa...
Prostate cancer (PCa) is the most common cancer diagnosis and the second most common cause of cancer...
Despite advances in molecular medicine, genomics, proteomics and translational research, prostate ca...
Prostate cancer (PCa) is the most common cancer diagnosis and the second most common cause of cancer...
Prostate cancer (PCa) is the most common cancer diagnosis and the second most common cause of cancer...
Prostate cancer (PCa) is the most common cancer diagnosis and the second most common cause of cancer...
The marker currently used for prostate cancer (CaP) detection is an increase in serum prostate-speci...
Prostate cancer (PCa) is one of the most frequently diagnosed cancer among men in the western societ...
International audienceSimple Summary Despite intensive research, effective tools for detection and m...
International audienceSimple Summary Despite intensive research, effective tools for detection and m...
Early detection of prostate cancer is problematic due to the lack of a marker that has high diagnost...